Skin in the Game
We read the research so you don’t have to.
As a Dermatology podcast, we do things a little differently: we start every episode with immediately actionable clinical pearls—right up front. No fluff, no waiting.
So even if you’ve got five minutes between patients, you’ll still walk away with something you can actually use in clinic that day.
And if you want more—the “why,” the nuance, the deeper dive into the data—just keep listening.
Think of it as dermatology on your terms: quick when you need it, more when you want it.
We’re not here to just read papers and repeat the results.
We’re here to take the data, the ideas, the nuance—and make them more approachable, more usable…and ultimately more relevant to what actually happens in clinic.
Episodes
14 episodes
New Data, Who Dis? Fall Clinical 2026 pt 1
What happens in Vegas doesn’t always stay in Vegas especially when it comes to dermatology! Diego and Graham unpack the latest data, emerging therapies, and practice-changing insights from Fall Clinical 2026. From exciting breakthro...
Isotretinoin Labs, Lymphoma & Losing Sight: What’s the Real Risk?
Are we over-monitoring isotretinoin and overreacting to Dupixent safety signals? We unpack the evidence behind moving away from routine lab monitoring with isotretinoin, then tackle two of Dupixent’s most controversial reported adverse events: ...
Beyond the Blade: Skin Cancer Without Surgery & Live Vaccines on Dupixent
Can we skip the scalpel? We break down the latest evidence for nonsurgical treatment of keratinocyte carcinomas, including when these approaches make sense and where surgery still reigns supreme. Then, we revisit an old precaution: avoiding liv...
From Bald to Bold - and Dry to Wet
This week, we tackle two very different topics: the emerging evidence for upadacitinib in alopecia areata, and new data challenging the long-standing surgical dogma of keeping wounds dry after dermatologic surgery.
Dermatitis Flares & IL-31: Real or Imagined?
Dermatitis flares are common but should we really accept them as inevitable?Are they more closely linked to IL-31 blockade compared to the other MOAs used in AD treatment?In this episode of Skin in the Game, we challenge ...
Wheal Talk: Comparing CSU Treatments
With new therapies rapidly expanding the CSU treatment landscape, which options actually come out on top? We unpack a recent meta-analysis comparing efficacy across treatments and discuss what the rankings mean for real-world treatment decision...
The Biosimilar Paradox: Cheaper Drug, Bigger Bill
Biosimilars promise lower drug costs - but are patients actually saving? We unpack the surprising reality that despite lower prices, biosimilars can leave patients with higher out-of-pocket costs and discuss what this means for access and affor...
Beyond Morning Stiffness: Seeing the Damage in PsA with Dr. David Oberlin
Radiographic progression in psoriatic arthritis isn’t always as straightforward as the headline results suggest. We discuss David Oberlin’s recent JAAD paper examining IL-23 inhibitor trials, why trial design matters when interpreting structura...
To Cut or Not to Cut? The Dysplastic Nevus Discussion
Few topics in dermatology generate more debate than the management of dysplastic nevi. Should every positive margin be re-excised? Does the degree of atypia matter? And what does the evidence actually tell us about melanoma risk?In this ...
From Black Box to Bargain Price: The Tofacitinib Comeback?
Tofacitinib was the first oral JAK inhibitor to transform the treatment of inflammatory disease but after the ORAL Surveillance trial, its boxed warning reshaped how many clinicians viewed the entire class.Now, everything is changing aga...
Which Psoriasis Therapy Comes Out on Top? Breaking Down the Latest Network Meta-Analysis
With more treatment options than ever, choosing the right therapy for psoriasis isn’t always straightforward. In this episode of Skin in the Game, we break down the latest JAMA Dermatology meta-analysis comparing systemic treatm...
The IDENTITY Trial - Can Precision Medicine Transform Atopic Dermatitis Care?
For decades, systemic therapy selection in atopic dermatitis has largely relied on clinical judgment and trial-and-error. The prospective IDENTITY study by Silverberg and colleagues challenges that paradigm.In this episode of S...
Finasteride, Dutasteride & Sexual Side Effects - What Does the Evidence Really Show?
Few topics in dermatology spark more debate than the sexual side effects of oral finasteride. In this episode of Skin in the Game, we break down the latest evidence comparing finasteride and dutasteride, including a new pharmacovigilance...
Getting Some Skin in the Game
Welcome to Skin in the Game, a dermatology podcast delivering high-yield clinical pearls for busy clinicians. Hosted by dermatologists Graham Litchman and Diego Ruiz Dasilva: we break down the latest research and translate it into practical ins...